false
0001506983
0001506983
2026-10-22
2026-10-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 22, 2026
GLUCOTRACK,
INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41141 |
|
98-0668934 |
| (State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
| 301
Rte. 17 North, Ste. 800, Rutherford, NJ |
|
07070 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 842-7715
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock |
|
GCTK |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry Into a Material Definitive Agreement.
Private
Placement
On
October 22, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase
Agreement”) with certain investors (the “Investors”), pursuant to which the Company issued to the Investors senior
secured convertible promissory notes (the “Notes”) in the aggregate principal amount of $2,564,102.65 for an aggregate cash
purchase price of $2,000,000, reflecting a 22% original issue discount. The Notes bear interest at a rate of 8% per annum on the outstanding
principal amount and mature nine (9) months after their issuance on October 22, 2026. Upon the occurrence of any Event of Default
(as defined in the Notes), the outstanding principal amount, together with any past due and unpaid interest, will bear interest at a
rate of 18% per annum until paid in full. The Notes are secured by a security interest in substantially all of the assets of the Company
and its subsidiaries pursuant to the Company’s existing security agreement and rank equally and ratably in the collateral with
the Company’s other outstanding obligations secured thereunder.
The
Notes are convertible, in whole or in part, at any time on or after the issuance date, at a conversion price equal to the lower of (i)
$0.6390, representing the Nasdaq Minimum Price (as defined in the Note) and (ii) 80% of the lowest daily volume weighted average
price of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) during the fifteen (15) trading
days immediately preceding the applicable conversion notice, subject in each case to a floor price equal to 20% of the Nasdaq Minimum
Price (the “Floor Price”) (the “Conversion Price”). The total cumulative number of shares of Common Stock
issued upon conversion of the Notes and exercise of the Warrants (as defined below), in the aggregate, may not exceed 19.99% of
the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the “Exchange Cap”), unless and
until the Company obtains stockholder approval of the issuance of the underlying Common Stock in accordance with Nasdaq Listing Rule
5635(d) (the “Stockholder Approval”). If the volume weighted average price of the Common Stock is less than the Floor Price
then in effect on each of any ten (10) consecutive trading days, the Floor Price shall, subject to the Company’s receipt of the
Stockholder Approval, automatically reset to, and thereafter equal, the lowest volume weighted average price during such ten (10) trading
day period. The Conversion Price and Floor Price are subject to adjustment for stock splits, stock combinations, stock dividends, reclassifications,
dilutive issuances, share combination events, and reorganization or change of control transactions.
The
sale of the Notes and Warrants (as described below) is referred to herein as the “Financing.” The Financing closed on October
22, 2026 (the “Closing”), resulting in gross proceeds to the Company of $2,000,000, before deducting the Placement
Agent’s fees and other offering expenses. The Purchase Agreement, the Notes and the Warrants are collectively referred to herein
as the “Transaction Documents.”
Warrants
On
October 22, 2026,
the Company also issued to the Investors warrants (the “Warrants” and, together with the Notes, the “Securities”)
to purchase 8,025,360 shares
of Common Stock, representing a number of shares equal to 200% of
each Investor’s principal amount under its Note divided by $0.6390. The
Warrants are exercisable for a period of five (5) years from the date of issuance at an exercise price of $1.5975
per share; provided that, in each case, the shares of Common
Stock issuable upon exercise of the Warrants are subject to the Exchange Cap and may not be issued in excess thereof unless and until
the Company obtains the Stockholder Approval. The exercise price and the number of shares of Common Stock issuable upon exercise of the
Warrants is subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations,
reclassifications or similar events affecting the Common Stock.
Other
Terms of Purchase Agreement
Registration
Rights
The
Company is required to file a registration statement (or add the shares of Common Stock issuable upon conversion of the Notes and exercise
of the Warrants (the “Registrable Securities”) to an existing registration statement on file with the Securities and Exchange
Commission (the “SEC”) that has not yet been declared effective) within ten (10) days after the Closing (the “Required
Filing Registration Date”) covering the resale of Registrable Securities. The Company is required to use commercially reasonable
efforts to cause such registration statement to be declared effective within forty-five (45) days of the Closing (the “Required
Effective Registration Date”). If the registration statement is not filed by the Required Filing Registration Date, the Company
shall issue and deliver to the Investors a number of shares of Common Stock equal to $250,000 divided by the lowest traded price of the
Common Stock between the Closing and the Required Filing Registration Date, and for every thirty (30) days thereafter that the registration
statement is not filed, the Company shall issue and deliver to the Investors a number of additional shares of Common Stock equal to $250,000
divided by the lowest traded price of the Common Stock during such thirty (30) day period, subject to an aggregate cap of $1,500,000
in shares (collectively with any shares issuable pursuant to a failure to achieve effectiveness of the registration statement by the
Required Effective Registration Date or a failure to obtain the Stockholder Approval, the “Penalty Shares”). If the registration
statement is not declared effective by the Required Effective Registration Date, the Company shall issue and deliver to the Investors
a number of shares of Common Stock equal to $250,000 divided by the lowest traded price of the Common Stock between the Closing and the
Required Effective Registration Date, and for every thirty (30) days thereafter that the registration statement is not declared effective,
the Company shall issue and deliver to the Investors a number of additional shares of Common Stock equal to $250,000 divided by the lowest
traded price of the Common Stock during such thirty (30) day period. To the extent the issuance of any Penalty Shares, when aggregated
with the other shares of Common Stock issued or issuable under the Transaction Documents, would exceed the Exchange Cap, such
Penalty Shares shall not be issued until the Company has obtained the Stockholder Approval.
Stockholder
Approval
Within
thirty (30) days of the Closing (the “Required Initial Proxy Date”), the Company is required to file a proxy statement with
the SEC for the purpose of obtaining the Stockholder Approval. The Company is required to use its commercially best efforts to obtain
the Stockholder Approval within ninety (90) days of the Closing (the “Required Stockholder Meeting Date”). If the proxy statement
is not filed by the Required Initial Proxy Date, the Company shall issue and deliver to the Investors a number of shares of Common Stock
equal to $250,000 divided by the lowest traded price of the Common Stock between the Closing and the Required Initial Proxy Date. For
every thirty (30) days after the Required Stockholder Meeting Date that the stockholder meeting is not held, the Company shall issue
and deliver to the Investors a number of additional shares of Common Stock equal to $250,000 divided by the lowest traded price of the
Common Stock during such thirty (30) day period. To the extent the issuance of any Penalty Shares would, when aggregated with the other
shares of Common Stock issued or issuable under the Transaction Documents, exceed the Exchange Cap, such Penalty Shares shall
not be issued until the Company has obtained the Stockholder Approval. If the Stockholder Approval is not obtained by the first Required
Stockholder Meeting Date, the Company shall, during the period beginning on such date and continuing 360 days thereafter, cause an additional
stockholder meeting to be held every sixty (60) days until the Stockholder Approval is obtained.
Most
Favored Nation
While
any Notes remain outstanding, upon any issuance by the Company of its securities for cash consideration (a “Subsequent Financing”),
each Investor may elect, in its sole discretion, to exchange all or some of the Securities then held for any securities or units issued
in a Subsequent Financing on a dollar-for-dollar basis. The Company is required to provide each Investor with notice of any Subsequent
Financing. Additionally, if in any Subsequent Financing there are any contractual provisions or side letters that provide terms more
favorable to the investors therein than the terms provided under the Transaction Documents, then the Company shall notify the Investors
of such additional or more favorable terms and such terms, at each Investor’s option, shall become a part of the Transaction Documents.
Additionally, if the Company enters into any subsequent financing with another individual or entity on terms that are more favorable
than those provided to the Investors, the Transaction Documents shall automatically be amended to include such more favorable terms,
so long as the Notes remain outstanding. The foregoing most favored nations provisions do not apply to Exempted Securities (as defined
in the Purchase Agreement) or to securities of any subsidiary.
Subsequent
Equity Sales
From
the Closing until ninety (90) days following the effective date of each of the registration statement and Stockholder Approval, the Company
and any subsidiary shall not (i) issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares
of Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement), other than Exempted Securities, or (ii) file any
registration statement or any amendment or supplement thereto, in each case other than (A) solely with respect to securities issued pursuant
to any share or option plan duly adopted for such purpose by the Company’s board of directors or a committee of non-employee directors
established for such purpose for services rendered to the Company, or (B) a registration statement filed in connection with a Registered
Public Offering (as defined in the Purchase Agreement). While the Notes remain outstanding, the Company and its subsidiaries may not
enter into a Variable Rate Transaction, as defined in the Purchase Agreement, without the prior written consent of the Investors. Variable
Rate Transactions generally include issuances of securities with conversion, exercise or exchange prices based on or varying with future
trading prices of the Common Stock, securities containing specified future price-reset features, and equity lines of credit or similar
continuous offerings at future-determined prices. The restriction is subject to the exceptions set forth in the Purchase Agreement.
Mandatory
Repayment from ELOC Proceeds
Until
all outstanding principal, accrued and unpaid interest and other amounts owing under each Note have been paid in full, the Company shall,
and shall cause each of its subsidiaries to, apply fifty percent (50%) of all proceeds received under any equity line of credit or similar
arrangement (each, an “ELOC,” and such proceeds, “ELOC Proceeds”) toward the repayment of each Note. Such obligation
is mandatory and not subject to any election, waiver or discretion of the Company, and shall apply separately to each draw, advance,
put or tranche under any ELOC as and when the related ELOC Proceeds are received. The Company shall pay such amount to each Investor
in immediately available funds within three (3) business days following the Company’s or any subsidiary’s receipt of the
applicable ELOC Proceeds, and such payment shall be applied first to accrued and unpaid interest and other amounts (other than principal)
owing under the Note and thereafter to the outstanding principal amount. Concurrently with each such payment, the Company shall deliver
to each Investor a written notice setting forth the date and amount of the applicable draw or tranche and the ELOC Proceeds received.
No such repayment shall be subject to any prepayment premium or penalty under the Notes, and no such repayment shall limit any other
right of the Investors under the Notes or the other Transaction Documents. The failure of the Company to make any repayment required
by the Purchase Agreement within such three (3) business day period shall constitute an Event of Default (as such term is defined in
the Notes).
Placement
Agency Agreement
In
connection with the Private Placement, on October 22, 2026,
the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Dawson James Securities, Inc.
(the “Placement Agent”). As compensation for acting as Placement Agent for the Financing, the Company agreed to pay the Placement
Agent (a) a cash placement fee equal to seven percent (7%) of the gross cash proceeds received by the Company from the sale of the Securities,
(b) warrants (the “Placement Agent Warrants”) to purchase 160,508 shares
of Common Stock, representing a number of shares equal to four percent (4.0%) of the aggregate number of shares of Common Stock initially
issuable upon conversion in full of the Notes issued to the Investors at the Closing, calculated using the initial Conversion Price,
which Placement Agent Warrants are exercisable at any time and from time to time, in whole or in part, during the five-year period from
the Closing Date, at a price per share equal to one hundred twenty-five percent (125%) of the initial Conversion Price, and (c) reimbursement
of the Placement Agent’s actual accountable expenses, including legal and diligence expenses, in an aggregate amount not to exceed
$50,000.
The
above summary of the Notes, the Warrants, the Placement Agent Warrants, the Purchase Agreement, and the Placement Agency Agreement does
not purport to be complete and is qualified in its entirety by reference to such applicable agreements or forms of agreements, copies
of which are attached as Exhibits 4.1, 4.2, 4.3, 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein
by reference.
Item
2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The
disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.
Item
3.02. Unregistered Sales of Equity Securities.
The
disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.02 by reference.
The
Notes, the Warrants, the Placement Agent Warrants and the shares of Common Stock issuable upon conversion of the Notes or exercise of
the Warrants or Placement Agent Warrants, as applicable, and any Penalty Shares that may be issued, were, or upon issuance will be, issued
and sold by the Company in reliance upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as
amended (the “Securities Act”).
As
previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on October 19, 2026 (the “Prior Form
8-K”), on October 13, 2026, the Company entered into a Waiver Agreement (the “Waiver”) with certain holders (the
“July Holders”) of warrants issued pursuant to the Securities Purchase Agreement, dated as of July 14, 2026, by and
among the Company and the July Holders, pursuant to which, in consideration for the Waiver, the Company became obligated to issue
new warrants (the “New Warrants”) to purchase an aggregate of 406,198 shares of Common Stock to the July Holders that
executed the Waiver. Since the filing of the Prior Form 8-K, additional July Holders have executed the Waiver and, in consideration
therefor, the Company has become obligated to issue to such additional New Warrants to purchase an aggregate of 270,300 additional
shares of Common Stock, bringing the aggregate number of shares of Common Stock issuable upon exercise of the New Warrants to
676,498. The additional New Warrants have the same terms as the New Warrants described in the Prior Form 8-K, which description is incorporated herein by reference. The New Warrants and
the shares of Common Stock issuable upon exercise thereof will be issued by the Company to the July Holders in reliance upon the
exemption from the registration afforded by Section 4(a)(2) of the Securities Act.
Item
7.01. Regulation FD Disclosure.
On
October 22, 2026, the Company issued a press release, which announced a 1-for-2 reverse stock split of the Company’s common
stock, par value $0.001 per share, effective with the opening of trading on October 26, 2026. A copy of the press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K.
The
information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or
specifically incorporates it by reference into a filing under the Securities Act or the Exchange Act.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 4.1 |
|
Form
of Note, dated October 22 2026 |
| 4.2 |
|
Form
of Warrant, dated October 22, 2026 |
| 4.3 |
|
Form
of Placement Agent Warrant, dated October 22, 2026 |
| 10.1 |
|
Form
of Securities Purchase Agreement, dated October 22, 2026, by and between Glucotrack, Inc. and the purchasers party thereto |
| 10.2 |
|
Placement
Agency Agreement, dated October 22, 2026, by and between Glucotrack, Inc. and Dawson James Securities, Inc. |
99.1
|
|
Press
Release, dated October 22, 2026
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
October 22, 2026 |
|
|
| |
|
|
| |
GLUCOTRACK,
INC. |
| |
|
|
| |
By: |
/s/
Erik Emerson |
| |
Name: |
Erik
Emerson |
| |
Title: |
Chief
Executive Officer |
Exhibit
99.1
Glucotrack,
Inc. Announces Reverse Stock Split
1-for-2
reverse stock split to become effective as of the opening of trading on October 26, 2026
RUTHERFORD,
N.J., and LA JOLLA, C.A., October 22, 2026 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”),
a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™, today
announced that it will effect a 1-for-2 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common
stock, par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, October 26, 2026.
Glucotrack’s
Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK.” The new
CUSIP number for the Common Stock following the Reverse Stock Split will be 45824Q879.
The
material effects of the Reverse Stock Split will be:
| ● | Every
two (2) shares of Glucotrack’s issued and outstanding Common Stock will be combined
into one (1) share of Common Stock. |
| ● | The
number of total outstanding shares of Common Stock will be proportionally reduced from 2,368,237
shares to approximately 1,184,119 shares. |
| ● | The
ownership percentage of each Glucotrack stockholder will remain unchanged, other than as
a result of fractional shares. No fractional shares of Common Stock will be issued in connection
with the Reverse Stock Split. Instead, stockholders who otherwise would be entitled to receive
fractional shares because they hold a number of shares not evenly divisible by the Reverse
Stock Split ratio will automatically be entitled to receive an additional fraction of a share
of Common Stock to round up to the next whole share. |
At
the annual meeting of stockholders held on August 18, 2026, the stockholders of the Company approved a proposal to authorize the Company’s
management to file one or more certificates of amendment to the Company’s certificate of incorporation to effect one or more reverse
stock splits at an aggregate ratio not to exceed 1-for-30, as determined by the Company’s management in its sole discretion. On
August 28, 2026, the Company implemented a 1-for-15 reverse stock split.
Among
other considerations, the Reverse Stock Split is intended to help Glucotrack regain compliance with the $1.00 minimum bid price requirement
for continued listing of its Common Stock on Nasdaq under Nasdaq Listing Rule 5550(a)(2) and to make the prevailing price of its Common
Stock more attractive to a broader group of institutional investors. Under the terms of the exception granted to the Company by the Nasdaq
Hearings Panel (the “Panel”), the Company must maintain a closing bid price of at least $1.00 for each trading day until
November 9, 2026. In addition, if the Company becomes non-compliant with any other Nasdaq Listing Rule during the term of the exception,
it will have seven (7) calendar days to advise the Panel of its plan to cure the deficiency, and the Panel will then determine whether
to grant the Company an exception to cure the deficiency or to delist the Company. The Panel has also reserved the right to reconsider
the terms of the exception based on any event, condition or circumstance that, in the opinion of the Panel, would make continued listing
of the Company’s securities on Nasdaq inadvisable or unwarranted. Accordingly, if the Company fails to satisfy the terms of the
exception, or if the Panel reconsiders those terms, the Company’s securities may be delisted from Nasdaq.
The
combination of, and reduction in, the number of issued and outstanding shares of Common Stock as a result of the Reverse Stock Split
will occur automatically at the opening of trading on October 26, 2026, without any additional action on the part of Glucotrack’s
stockholders. Glucotrack’s transfer agent, VStock Transfer, LLC, is acting as the exchange agent for the Reverse Stock Split and
will send each stockholder a transaction statement indicating the number of shares of Common Stock the stockholder holds after the Reverse
Stock Split. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to
reflect the Reverse Stock Split, subject to such nominee’s particular processes. Such stockholders will not be required to take
any action in connection with the Reverse Stock Split.
Additional
information regarding the Reverse Stock Split can be found in the Company’s Definitive Proxy Statement on Schedule 14A, filed with
the U.S. Securities and Exchange Commission on July 17, 2026. A link to this document is available at https://www.sec.gov.
About
Glucotrack, Inc.
Glucotrack,
Inc. (Nasdaq: GCTK) operates Lōkahi Therapeutics™, a biopharmaceutical platform focused on advancing innovative therapeutic
opportunities through disciplined evaluation, strategic development, and collaborative discovery. Through its ai² platform, Lōkahi
Therapeutics™ seeks to identify, evaluate, and advance differentiated healthcare and life sciences opportunities. For more information,
please visit www.lokahithera.com. In addition, through its subsidiary Glucotrack Technologies, Inc., the Company is focused on
the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous
blood glucose monitoring system. The Glucotrack CBGM is an investigational device and is limited by federal (or United States) law to
investigational use. For more information, please visit www.glucotrack.com. Information on the Company’s website does not
constitute a part of and is not incorporated by reference into this press release.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements
contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting
the generality of the foregoing, words such as “anticipate,” “believe,” “expect,” “intend,”
“plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based
on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate
only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking
statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results
anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects
on Glucotrack or its business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual
results and could cause such results to differ materially from any forward-looking statements that may be made in this press release.
These factors include, but are not limited to: the anticipated benefits of the Reverse Stock Split, including the effect the Reverse
Stock Split will have on the Company’s ability to maintain compliance with the Nasdaq listing standards; the effect of the Reverse
Stock Split on the market price and liquidity of the Common Stock; the Company’s ability to maintain a closing bid price of at
least $1.00 for each trading day until November 9, 2026; the Company’s ability to comply with the terms of the exception granted
by the Panel and with other Nasdaq listing requirements, and the Panel’s discretion to grant or deny any further exception or to
reconsider the terms of the exception; the risk that the Company’s securities may be delisted from Nasdaq if it fails to maintain
compliance with applicable listing requirements; the ability to make the Company’s Common Stock more attractive to institutional
investors; the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity
offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals
(including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials;
risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel;
and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”),
including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
Contacts:
Investor
Relations:
ir@lokahithera.com
